Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study

Area of Science:

• Cardiology
• Pharmacology
• Clinical Research

Background:

• Four new oral anticoagulants (NOACs) approved since 2010 supplement warfarin for thromboembolic disease.
• Limited head-to-head data hinders optimal selection between anticoagulants, balancing efficacy and bleeding risk.

Purpose of the Study:

• To compare the effectiveness and safety of dabigatran, apixaban, rivaroxaban, edoxaban, and warfarin for extended treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE).
• To evaluate treatment outcomes in specific patient sub-populations and assess the generalizability of findings across diverse US patient groups.

Main Methods:

• Comparative effectiveness research study involving five oral anticoagulant agents.
• Analysis of extended treatment versus no extended treatment for DVT and PE.
• Inclusion of Medicare, commercially insured, and Medicaid patients to ensure broad applicability.

Main Results:

• The study provides crucial head-to-head comparative data on five oral anticoagulants.
• Findings are generalizable to the majority of US patients with DVT or PE, including novel anticoagulant users.

Conclusions:

• This research offers essential guidance for clinicians and patients in selecting oral anticoagulants for DVT and PE.
• The study addresses the need for evidence-based strategies to optimize treatment outcomes and minimize bleeding risks.